Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 5/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30001251 | 1.00 | HSD17B10 (0.56) | HSD17B10KMT2AALDH1A1VCAM1PDE7A | |
| SCHEMBL27796780 | 0.86 | HSD17B10 (0.56) | HSD17B10KMT2AALDH1A1VCAM1GSK3B | |
| SCHEMBL508763 | 0.86 | HSD17B10 (0.60) | HSD17B10KMT2AALDH1A1VCAM1PDE7A | |
| SCHEMBL29672035 | 0.86 | HSD17B10 (0.60) | HSD17B10KMT2AALDH1A1VCAM1PDE7A | |
| SCHEMBL23883005 | 0.83 | HSD17B10 (0.56) | HSD17B10KMT2AALDH1A1VCAM1PDE7A | |
| SCHEMBL11369484 | 0.83 | HSD17B10 (0.56) | HSD17B10KMT2AALDH1A1VCAM1PDE7A | |
| SCHEMBL28239875 | 0.83 | HSD17B10 (0.56) | HSD17B10KMT2AALDH1A1VCAM1PDE7A | |
| SCHEMBL30002362 | 0.83 | HSD17B10 (0.56) | HSD17B10KMT2AALDH1A1VCAM1PDE7A | |
| SCHEMBL30001924 | 0.83 | HSD17B10 (0.56) | HSD17B10KMT2AALDH1A1VCAM1PDE7A | |
| SCHEMBL2589891 | 0.83 | HSD17B10 (0.56) | HSD17B10KMT2AALDH1A1VCAM1PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333407-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250144230-A1 | LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES | ORUM THERAPEUTICS, INC. (KR) | 2025-05-08 | — | — | US | disclosed |
| US-20240252671-A1 | NEODEGRADER-ANTI-CD33 ANTIBODY CONJUGATES | ORUM THERAPEUTICS INC (KR) | 2024-08-01 | — | — | US | disclosed |
| EP-4398942-A1 | LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES | Orum Therapeutics Inc. (KR) | 2024-07-17 | — | — | EP | disclosed |
| CN-118201641-A | Novel degradant-anti-CD 33 antibody conjugates | 奥隆制药 | 2024-06-14 | — | — | CN | disclosed |
| CN-118201642-A | Linker for antibody drug conjugates | 奥隆制药 | 2024-06-14 | — | — | CN | disclosed |
| US-20230338564-A1 | NEODEGRADER CONJUGATES | ORUM THERAPEUTICS, INC. (FR) | 2023-10-26 | — | — | US | disclosed |
| CN-115867322-A | Novel degradant conjugates | 奥隆制药 | 2023-03-28 | — | — | CN | disclosed |
| WO-2023037268-A1 | LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES | ORUM THERAPEUTICS, INC. (KR) | 2023-03-16 | — | — | WO | disclosed |
| EP-4126067-A1 | NEODEGRADER CONJUGATES | Orum Therapeutics Inc. (KR) | 2023-02-08 | — | — | EP | disclosed |
| CN-103044432-A | Bicyclic heteroaryl compounds | ARIAD PHARMA INC | 2013-04-17 | — | — | CN | disclosed |
| EP-2569290-A2 | PHARMACEUTICAL COMPOUNDS | Sentinel Oncology Limited (GB) | 2013-03-20 | — | — | EP | disclosed |
| US-20130065900-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| WO-2011141716-A2 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2011-11-17 | — | — | WO | disclosed |
| CN-101490053-A | Monocyclic Heteroaryl Compounds | ARIAD PHARMA INC (US) | 2009-07-22 | — | — | CN | disclosed |
| CN-1165532-C | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | ���Ͽع�����˾ | 2004-09-08 | — | — | CN | disclosed |
| EP-1043308-B1 | PHENYLAMINOALKYLCARBOXYLIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-6353025-B1 | COMPOUNDS AS DRUGS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| CN-1320121-A | Substituted 3-cyanoquinolines as protein tyrosine kinase inhibitors | AMERICAN CYANAMID CO (US) | 2001-10-31 | — | — | CN | disclosed |
| EP-1043308-A1 | PHENYLAMINOALKYLCARBOXYLIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252671-A1 | NEODEGRADER-ANTI-CD33 ANTIBODY CONJUGATES | NEU3, FCGR3B, ENTPD3 | HSD17B10 2571/4885KMT2A 2655/4885ALDH1A1 685/4885 |
| US-20130065900-A1 | PHARMACEUTICAL COMPOUNDS | CSNK1A1, FRK, CSNK1E | HSD17B10 2176/4885KMT2A 1629/4885ALDH1A1 3289/4885 |
| US-20230338564-A1 | NEODEGRADER CONJUGATES | CD44, FOLR1, CD47 | HSD17B10 1567/4885KMT2A 2917/4885ALDH1A1 275/4885 |
| US-20250144230-A1 | LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES | CD2BP2, CD47, EPCAM | HSD17B10 3930/4885KMT2A 1804/4885ALDH1A1 2708/4885 |
| US-20250333407-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBG1, HBG2, HBB | HSD17B10 658/4885KMT2A 1728/4885ALDH1A1 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.